{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T07:49:16Z","timestamp":1792309756522,"version":"4.4.0"},"reference-count":244,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:00:00Z","timestamp":1620950400000},"content-version":"am","delay-in-days":347,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["16-IDEX-0001 CAP 20-25"],"award-info":[{"award-number":["16-IDEX-0001 CAP 20-25"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.pharmthera.2020.107519","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T13:06:51Z","timestamp":1583759211000},"page":"107519","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Replacement of current opioid drugs focusing on MOR-related strategies"],"prefix":"10.1016","volume":"210","author":[{"given":"J\u00e9r\u00f4me","family":"Busserolles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Lolignier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Kerckhove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9lian","family":"Bertin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Authier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Eschalier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.pharmthera.2020.107519_bb0005","doi-asserted-by":"crossref","first-page":"8721","DOI":"10.1523\/JNEUROSCI.17-22-08721.1997","article-title":"Nociceptin inhibits T-type Ca2+ channel current in rat sensory neurons by a G-protein-independent mechanism","volume":"17","author":"Abdulla","year":"1997","journal-title":"The Journal of Neuroscience: The Official Journal of the Society for Neuroscience"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107519_bb0010","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1021\/acschemneuro.8b00370","article-title":"Analgesic effects of the GIRK activator, VU0466551, alone and in combination with morphine in acute and persistent pain models","volume":"10","author":"Abney","year":"2019","journal-title":"ACS Chemical Neuroscience"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107519_bb0015","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1038\/sj.emboj.7601116","article-title":"TREK-1, a K+ channel involved in polymodal pain perception","volume":"25","author":"Alloui","year":"2006","journal-title":"The EMBO Journal"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107519_bb0020","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1177\/0269881116689257","article-title":"Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents","volume":"31","author":"Altarifi","year":"2017","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107519_bb0025","doi-asserted-by":"crossref","first-page":"5100","DOI":"10.3390\/md11125100","article-title":"Polypeptide modulators of TRPV1 produce analgesia without hyperthermia","volume":"11","author":"Andreev","year":"2013","journal-title":"Marine Drugs"},{"key":"10.1016\/j.pharmthera.2020.107519_bb0035","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.neuroscience.2018.10.015","article-title":"Mu-opioid receptor (MOR) biased agonists induce biphasic dose-dependent hyperalgesia and analgesia, and Hyperalgesic priming in the rat","volume":"394","author":"Araldi","year":"2018","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2020.107519_bb0040","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.drugalcdep.2018.08.002","article-title":"The G-protein biased mu-opioid agonist, TRV130, produces reinforcing and antinociceptive effects that are comparable to oxycodone in rats","volume":"192","author":"Austin Zamarripa","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107519_bb0045","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S1053-0770(05)80137-5","article-title":"Comparison of intrapleural versus intravenous morphine for postthoracotomy pain management","volume":"9","author":"Ayka\u00e7","year":"1995","journal-title":"Journal of Cardiothoracic and Vascular Anesthesia"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107519_bb0050","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1085\/jgp.201411336","article-title":"Transient receptor potential melastatin 3 is a phosphoinositide-dependent ion channel","volume":"146","author":"Badheka","year":"2015","journal-title":"The Journal of General Physiology"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107519_bb0055","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.tips.2008.07.013","article-title":"Emerging roles for two-pore-domain potassium channels and their potential therapeutic impact","volume":"29","author":"Bayliss","year":"2008","journal-title":"Trends in Pharmacological Sciences"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107519_bb0060","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nn1180","article-title":"Agonist-independent modulation of N-type calcium channels by ORL1 receptors","volume":"7","author":"Beedle","year":"2004","journal-title":"Nature Neuroscience"},{"issue":"5552","key":"10.1016\/j.pharmthera.2020.107519_bb0065","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/260625a0","article-title":"Analgesia induced in vivo by central administration of enkephalin in rat","volume":"260","author":"Belluzzi","year":"1976","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107519_bb0070","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1073\/pnas.83.9.2797","article-title":"Beta-adrenergic receptor kinase: Identification of a novel protein kinase that phosphorylates the agonist-occupied form of the receptor","volume":"83","author":"Benovic","year":"1986","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107519_bb0075","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.2147\/JPR.S217563","article-title":"ATHENA: A phase 3, open-label study of the safety and effectiveness of Oliceridine (TRV130), A G-protein selective agonist at the \u03bc-opioid receptor, in patients with moderate to severe acute pain requiring parenteral opioid therapy","volume":"12","author":"Bergese","year":"2019","journal-title":"Journal of Pain Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107519_bb0080","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1471-4159.2009.06308.x","article-title":"Supraspinal Gbetagamma-dependent stimulation of PLCbeta originating from G inhibitory protein-mu opioid receptor-coupling is necessary for morphine induced acute hyperalgesia","volume":"111","author":"Bianchi","year":"2009","journal-title":"Journal of Neurochemistry"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107519_bb0085","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ejpain.2010.09.007","article-title":"A randomised controlled trial on the efficacy and side-effect profile (nausea\/vomiting\/sedation) of morphine-6-glucuronide versus morphine for post-operative pain relief after major abdominal surgery","volume":"15","author":"Binning","year":"2011","journal-title":"European Journal of Pain (London, England)"},{"issue":"6813","key":"10.1016\/j.pharmthera.2020.107519_bb0090","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/35047086","article-title":"Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence","volume":"408","author":"Bohn","year":"2000","journal-title":"Nature"},{"issue":"5449","key":"10.1016\/j.pharmthera.2020.107519_bb0095","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1126\/science.286.5449.2495","article-title":"Enhanced morphine analgesia in mice lacking beta-arrestin 2","volume":"286","author":"Bohn","year":"1999","journal-title":"Science (New York, N.Y.)"},{"issue":"32","key":"10.1016\/j.pharmthera.2020.107519_bb0100","doi-asserted-by":"crossref","first-page":"10265","DOI":"10.1523\/JNEUROSCI.23-32-10265.2003","article-title":"Enhanced rewarding properties of morphine, but not cocaine, in beta(arrestin)-2 knock-out mice","volume":"23","author":"Bohn","year":"2003","journal-title":"The Journal of Neuroscience: The Official Journal of the Society for Neuroscience"},{"issue":"23","key":"10.1016\/j.pharmthera.2020.107519_bb0105","doi-asserted-by":"crossref","first-page":"10494","DOI":"10.1523\/JNEUROSCI.22-23-10494.2002","article-title":"Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice","volume":"22","author":"Bohn","year":"2002","journal-title":"The Journal of Neuroscience: The Official Journal of the Society for Neuroscience"},{"issue":"5772","key":"10.1016\/j.pharmthera.2020.107519_bb0110","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1126\/science.1120378","article-title":"Differential targeting of Gbetagamma-subunit signaling with small molecules","volume":"312","author":"Bonacci","year":"2006","journal-title":"Science (New York, N.Y.)"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107519_bb0115","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.116","article-title":"Long-lasting oral analgesic effects of N-protected aminophosphinic dual ENKephalinase inhibitors (DENKIs) in peripherally controlled pain","volume":"3","author":"Bonnard","year":"2015","journal-title":"Pharmacology Research & Perspectives"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107519_bb0120","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1152\/jn.00249.2003","article-title":"fMRI measurement of CNS responses to naloxone infusion and subsequent mild noxious thermal stimuli in healthy volunteers","volume":"91","author":"Borras","year":"2004","journal-title":"Journal of Neurophysiology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107519_bb0125","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.pain.2007.08.013","article-title":"Prevalence of chronic pain with neuropathic characteristics in the general population","volume":"136","author":"Bouhassira","year":"2008","journal-title":"Pain"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107519_bb0130","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1155\/2007\/762180","article-title":"Chronic pain in Canada: Have we improved our management of chronic noncancer pain?","volume":"12","author":"Boulanger","year":"2007","journal-title":"Pain Research & Management"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107519_bb0135","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1152\/physrev.00023.2013","article-title":"Calcium-permeable ion channels in pain signaling","volume":"94","author":"Bourinet","year":"2014","journal-title":"Physiological Reviews"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107519_bb0140","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S0022-3565(25)33172-1","article-title":"Analgesic effects of intraventricular morphine and enkephalins in nondependent and morphine-dependent rats","volume":"222","author":"Brady","year":"1982","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107519_bb0145","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ejpain.2005.06.009","article-title":"Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment","volume":"10","author":"Breivik","year":"2006","journal-title":"European Journal of Pain"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107519_bb0150","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.14309\/ajg.0000000000000327","article-title":"Efficacy and safety of Eluxadoline in patients with irritable bowel syndrome with diarrhea who report inadequate symptom control with Loperamide: RELIEF phase 4 study","volume":"114","author":"Brenner","year":"2019","journal-title":"The American Journal of Gastroenterology"},{"issue":"23","key":"10.1016\/j.pharmthera.2020.107519_bb0155","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1001\/jama.2018.18472","article-title":"Opioids for chronic noncancer pain: A systematic review and meta-analysis","volume":"320","author":"Busse","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2020.107519_bb0160","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.brainres.2014.01.042","article-title":"Morphine inhibits acid-sensing ion channel currents in rat dorsal root ganglion neurons","volume":"1554","author":"Cai","year":"2014","journal-title":"Brain Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107519_bb0165","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nrcardio.2016.200","article-title":"Long-term neprilysin inhibition - implications for ARNIs","volume":"14","author":"Campbell","year":"2017","journal-title":"Nature Reviews Cardiology"},{"issue":"5464","key":"10.1016\/j.pharmthera.2020.107519_bb0170","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1126\/science.288.5464.306","article-title":"Impaired nociception and pain sensation in mice lacking the capsaicin receptor","volume":"288","author":"Caterina","year":"2000","journal-title":"Science (New York, N.Y.)"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107519_bb0175","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1073\/pnas.77.8.4469","article-title":"Possible role of distinct morphine and enkephalin receptors in mediating actins of benzomorphan drugs (putative kappa and sigma agonists)","volume":"77","author":"Chang","year":"1980","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107519_bb0180","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jpain.2010.02.019","article-title":"Opioid pharmacotherapy for chronic non-cancer pain in the United States: A research guideline for developing an evidence-base","volume":"11","author":"Chapman","year":"2010","journal-title":"The Journal of Pain: Official Journal of the American Pain Society"},{"issue":"21","key":"10.1016\/j.pharmthera.2020.107519_bb0185","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1021\/jm0102248","article-title":"Long lasting antinociceptive properties of enkephalin degrading enzyme (NEP and APN) inhibitor prodrugs","volume":"44","author":"Chen","year":"2001","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107519_bb0190","doi-asserted-by":"crossref","first-page":"5676","DOI":"10.1038\/srep05676","article-title":"Liquiritigenin alleviates mechanical and cold hyperalgesia in a rat neuropathic pain model","volume":"4","author":"Chen","year":"2014","journal-title":"Scientific Reports"},{"issue":"22","key":"10.1016\/j.pharmthera.2020.107519_bb0195","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.1523\/JNEUROSCI.4170-07.2008","article-title":"Activation of TRPV1 contributes to morphine tolerance: Involvement of the mitogen-activated protein kinase signaling pathway","volume":"28","author":"Chen","year":"2008","journal-title":"The Journal of Neuroscience: The Official Journal of the Society for Neuroscience"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107519_bb0200","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1097\/j.pain.0000000000001347","article-title":"Prevalence of chronic pain with or without neuropathic characteristics in France using the capture-recapture method: A population-based study","volume":"159","author":"Chenaf","year":"2018","journal-title":"Pain"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107519_bb0205","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.jpain.2016.08.010","article-title":"Codeine shopping behavior in a retrospective cohort of chronic noncancer pain patients: Incidence and risk factors","volume":"17","author":"Chenaf","year":"2016","journal-title":"The Journal of Pain"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107519_bb0210","doi-asserted-by":"crossref","first-page":"496","DOI":"10.12809\/hkmj164920","article-title":"Opioid therapy for chronic non-cancer pain: Guidelines for Hong Kong","volume":"22","author":"Cheung","year":"2016","journal-title":"Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107519_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpain.2008.10.008","article-title":"Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain","volume":"10","author":"Chou","year":"2009","journal-title":"The Journal of Pain"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107519_bb0220","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1001\/jamapsychiatry.2014.3043","article-title":"Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: Lessons learned from OxyContin","volume":"72","author":"Cicero","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pharmthera.2020.107519_bb0225","series-title":"Prescribing opioids for chronic pain in non-malignant disease","first-page":"205","author":"Coniam","year":"1989"},{"issue":"2\u20133","key":"10.1016\/j.pharmthera.2020.107519_bb0230","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0304-3959(99)00223-7","article-title":"Antagonists of excitatory opioid receptor functions enhance morphine\u2019s analgesic potency and attenuate opioid tolerance\/dependence liability","volume":"84","author":"Crain","year":"2000","journal-title":"Pain"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107519_bb0235","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0006-8993(88)90118-7","article-title":"Opioids excite rather than inhibit sensory neurons after chronic opioid exposure of spinal cord-ganglion cultures","volume":"455","author":"Crain","year":"1988","journal-title":"Brain Research"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107519_bb0240","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1073\/pnas.90.7.3019","article-title":"Direct coupling of opioid receptors to both stimulatory and inhibitory guanine nucleotide-binding proteins in F-11 neuroblastoma-sensory neuron hybrid cells","volume":"90","author":"Cruciani","year":"1993","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"15","key":"10.1016\/j.pharmthera.2020.107519_bb0245","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1523\/JNEUROSCI.0267-08.2008","article-title":"Absence and rescue of morphine withdrawal in GIRK\/Kir3 knock-out mice","volume":"28","author":"Cruz","year":"2008","journal-title":"The Journal of Neuroscience: The Official Journal of the Society for Neuroscience"},{"key":"10.1016\/j.pharmthera.2020.107519_bb0250","series-title":"MMWR. Morbidity and Mortality Weekly Report","first-page":"1001","article-title":"Prevalence of chronic pain and high-impact chronic pain among adults - United States, 2016","volume":"67(36)","author":"Dahlhamer","year":"2018"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107519_bb0255","doi-asserted-by":"crossref","first-page":"182","DOI":"10.2105\/AJPH.2017.304187","article-title":"Opioid crisis: No easy fix to its social and economic determinants","volume":"108","author":"Dasgupta","year":"2018","journal-title":"American Journal of Public Health"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107519_bb0260","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1046\/j.1471-4159.1996.67031301.x","article-title":"The dual peptidase inhibitor RB101 induces a long-lasting increase in the extracellular level of met-enkephalin-like material in the nucleus accumbens of freely moving rats","volume":"67","author":"Daug\u00e9","year":"1996","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2020.107519_bb0265","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.26280","article-title":"Anti-nociceptive action of peripheral mu-opioid receptors by G-beta-gamma protein-mediated inhibition of TRPM3 channels","volume":"6","author":"Dembla","year":"2017","journal-title":"ELife"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107519_bb0270","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/emmm.201100134","article-title":"Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors","volume":"3","author":"Descoeur","year":"2011","journal-title":"EMBO Molecular Medicine"},{"issue":"40883","key":"10.1016\/j.pharmthera.2020.107519_bb0275","article-title":"Pharmacological characterisation of the highly NaV1.7 selective spider venom peptide Pn3a","volume":"7","author":"Deuis","year":"2017","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2020.107519_bb0280","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1038\/ncomms3941","article-title":"Activation of TREK-1 by morphine results in analgesia without adverse side effects","volume":"4","author":"Devilliers","year":"2013","journal-title":"Nature Communications"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107519_bb0285","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1124\/jpet.112.201616","article-title":"A G protein-biased ligand at the \u03bc-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine","volume":"344","author":"DeWire","year":"2013","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"456","key":"10.1016\/j.pharmthera.2020.107519_bb0290","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar3483","article-title":"A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates","volume":"10","author":"Ding","year":"2018","journal-title":"Science Translational Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107519_bb0295","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0304-3959(01)00293-7","article-title":"L-type and T-type calcium channel blockade potentiate the analgesic effects of morphine and selective mu opioid agonist, but not to selective delta and kappa agonist at the level of the spinal cord in mice","volume":"93","author":"Do\u011frul","year":"2001","journal-title":"Pain"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107519_bb0300","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0024-3205(02)01736-8","article-title":"The role of T-type calcium channels in morphine analgesia, development of antinociceptive tolerance and dependence to morphine, and morphine abstinence syndrome","volume":"71","author":"Dogrul","year":"2002","journal-title":"Life Sciences"},{"key":"10.1016\/j.pharmthera.2020.107519_bb0305","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2147\/JPR.S105892","article-title":"A review of chronic pain impact on patients, their social environment and the health care system","volume":"9","author":"Due\u00f1as","year":"2016","journal-title":"Journal of Pain Research"},{"key":"10.1016\/j.pharmthera.2020.107519_bb0310","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.isci.2019.03.011","article-title":"Biased signaling of the mu opioid receptor revealed in native neurons","volume":"14","author":"Ehrlich","year":"2019","journal-title":"IScience"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107519_bb0320","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1517\/14728222.2016.1162295","article-title":"Nav1.7 and other voltage-gated sodium channels as drug targets for pain relief","volume":"20","author":"Emery","year":"2016","journal-title":"Expert Opinion on Therapeutic Targets"},{"key":"10.1016\/j.pharmthera.2020.107519_bb0325","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.pnpbp.2019.02.010","article-title":"Members of the same pharmacological family are not alike: Different opioids, different consequences, hope for the opioid crisis?","volume":"92","author":"Emery","year":"2019","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107519_bb0330","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1124\/mol.106.026740","article-title":"Mu-opioid receptor activation modulates transient receptor potential vanilloid 1 (TRPV1) currents in sensory neurons in a model of inflammatory pain","volume":"71","author":"Endres-Becker","year":"2007","journal-title":"Molecular Pharmacology"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107519_bb0335","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1152\/physrev.00029.2009","article-title":"Molecular background of leak K+ currents: Two-pore domain potassium channels","volume":"90","author":"Enyedi","year":"2010","journal-title":"Physiological Reviews"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107519_bb0340","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0304-3959(03)00225-2","article-title":"Epidemiology of chronic non-malignant pain in Denmark","volume":"106","author":"Eriksen","year":"2003","journal-title":"Pain"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107519_bb0345","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1074\/jbc.M109.040634","article-title":"Heterodimerization of ORL1 and opioid receptors and its consequences for N-type calcium channel regulation","volume":"285","author":"Evans","year":"2010","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107519_bb0350","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.neulet.2013.08.018","article-title":"Analgesics as reinforcers with chronic pain: Evidence from operant studies","volume":"557","author":"Ewan","year":"2013","journal-title":"Neuroscience Letters"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107519_bb0355","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aau5148","article-title":"A new painkiller nanomedicine to bypass the blood-brain barrier and the use of morphine","volume":"5","author":"Feng","year":"2019","journal-title":"Science Advances"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107519_bb0360","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/ana.22446","article-title":"Gene therapy for pain: Results of a phase I clinical trial","volume":"70","author":"Fink","year":"2011","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107519_bb0365","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.pain.2012.10.023","article-title":"State-dependent properties of a new T-type calcium channel blocker enhance ca(V)3.2 selectivity and support analgesic effects","volume":"154","author":"Francois","year":"2013","journal-title":"Pain"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107519_bb0370","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.tips.2007.06.005","article-title":"The evasive nature of drug efficacy: Implications for drug discovery","volume":"28","author":"Galandrin","year":"2007","journal-title":"Trends in Pharmacological Sciences"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107519_bb0375","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.bjae.2018.06.006","article-title":"Opioids for chronic non-cancer pain","volume":"18","author":"Gallagher","year":"2018","journal-title":"BJA Education"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107519_bb0380","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0026-895X(25)09190-4","article-title":"Multiple opioid receptors: Ligand selectivity profiles and binding site signatures","volume":"36","author":"Goldstein","year":"1989","journal-title":"Molecular Pharmacology"},{"issue":"29","key":"10.1016\/j.pharmthera.2020.107519_bb0385","doi-asserted-by":"crossref","first-page":"12072","DOI":"10.1073\/pnas.1222044110","article-title":"Identification of a \u03bc-\u03b4 opioid receptor heteromer-biased agonist with antinociceptive activity","volume":"110","author":"Gomes","year":"2013","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107519_bb0390","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.bbi.2017.01.014","article-title":"Hyperalgesic and hypoalgesic mechanisms evoked by the acute administration of CCL5 in mice","volume":"62","author":"Gonz\u00e1lez-Rodr\u00edguez","year":"2017","journal-title":"Brain, Behavior, and Immunity"},{"issue":"6599","key":"10.1016\/j.pharmthera.2020.107519_bb0395","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/383447a0","article-title":"Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2-adrenergic receptor","volume":"383","author":"Goodman","year":"1996","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107519_bb0400","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/syn.21914","article-title":"Mediation of buprenorphine analgesia by a combination of traditional and truncated mu opioid receptor splice variants","volume":"70","author":"Grinnell","year":"2016","journal-title":"Synapse (New York, N.Y.)"},{"key":"10.1016\/j.pharmthera.2020.107519_bb0405","article-title":"Long-term safety and tolerability of NKTR-181 in patients with moderate to severe chronic low Back pain or chronic noncancer pain: A phase 3 multicenter, open-label, 52-week study (SUMMIT-08 LTS)","author":"Gudin","year":"2019","journal-title":"Pain Medicine (Malden, Mass.)"},{"key":"10.1016\/j.pharmthera.2020.107519_bb0410","doi-asserted-by":"crossref","DOI":"10.1186\/s12990-015-0018-1","article-title":"Current gene therapy using viral vectors for chronic pain","volume":"11","author":"Guedon","year":"2015","journal-title":"Molecular Pain"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107519_bb0415","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/00000542-200504000-00018","article-title":"Randomized, double-blind study of the analgesic efficacy of morphine-6-glucuronide versus morphine sulfate for postoperative pain in major surgery","volume":"102","author":"Hanna","year":"2005","journal-title":"Anesthesiology"},{"issue":"43","key":"10.1016\/j.pharmthera.2020.107519_bb0420","first-page":"732","article-title":"Long-term opioid use in non-cancer pain","volume":"111","author":"H\u00e4user","year":"2014","journal-title":"Deutsches \u00c4rzteblatt International"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107519_bb0425","doi-asserted-by":"crossref","DOI":"10.1097\/PR9.0000000000000599","article-title":"The opioid epidemic and national guidelines for opioid therapy for chronic noncancer pain: A perspective from different continents","volume":"2","author":"H\u00e4user","year":"2017","journal-title":"Pain Reports"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107519_bb0430","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1523\/JNEUROSCI.4060-10.2011","article-title":"Multiple targets of \u03bc-opioid receptor-mediated presynaptic inhibition at primary afferent A\u03b4- and C-fibers","volume":"31","author":"Heinke","year":"2011","journal-title":"The Journal of Neuroscience: The Official Journal of the Society for Neuroscience"},{"issue":"13","key":"10.1016\/j.pharmthera.2020.107519_bb0435","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1111\/bph.14224","article-title":"The novel \u03bc-opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception","volume":"175","author":"Hill","year":"2018","journal-title":"British Journal of Pharmacology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107519_bb0440","doi-asserted-by":"crossref","first-page":"138","DOI":"10.47102\/annals-acadmedsg.V42N3p138","article-title":"Evidence-based guidelines on the use of opioids in chronic non-cancer pain--a consensus statement by the pain Association of Singapore Task Force","volume":"42","author":"Ho","year":"2013","journal-title":"Annals of the Academy of Medicine, Singapore"},{"issue":"5943","key":"10.1016\/j.pharmthera.2020.107519_bb0445","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/306611a0","article-title":"Isolation and structural organization of the human preproenkephalin B gene","volume":"306","author":"Horikawa","year":"1983","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107519_bb0450","doi-asserted-by":"crossref","first-page":"E199","DOI":"10.36076\/ppj.2013\/16\/E199","article-title":"Targeted nanoparticles that mimic immune cells in pain control inducing analgesic and anti-inflammatory actions: A potential novel treatment of acute and chronic pain condition","volume":"16","author":"Hua","year":"2013","journal-title":"Pain Physician"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107519_bb0455","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/0024-3205(75)90268-4","article-title":"Purification and properties of enkephalin - the possible endogenous ligand for the morphine receptor","volume":"16","author":"Hughes","year":"1975","journal-title":"Life Sciences"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107519_bb0460","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.neulet.2010.06.015","article-title":"G-protein-independent modulation of P-type calcium channels by mu-opioids in Purkinje neurons of rat","volume":"480","author":"Iegorova","year":"2010","journal-title":"Neuroscience Letters"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107519_bb0465","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0168-0102(00)00144-9","article-title":"Involvement of G-protein-activated inwardly rectifying K (GIRK) channels in opioid-induced analgesia","volume":"38","author":"Ikeda","year":"2000","journal-title":"Neuroscience Research"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107519_bb0470","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1016\/j.pain.2014.07.011","article-title":"Peripheral opioid receptor blockade increases postoperative morphine demands--a randomized, double-blind, placebo-controlled trial","volume":"155","author":"Jagla","year":"2014","journal-title":"Pain"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107519_bb0475","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1124\/jpet.103.052829","article-title":"Arylacetamide kappa-opioid receptor agonists produce a tonic- and use-dependent block of tetrodotoxin-sensitive and -resistant sodium currents in colon sensory neurons","volume":"307","author":"Joshi","year":"2003","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107519_bb0480","first-page":"1257","article-title":"Canadian guideline for safe and effective use of opioids for chronic noncancer pain: Clinical summary for family physicians. Part 1: General population","volume":"57","author":"Kahan","year":"2011","journal-title":"Canadian family physician Medecin de famille canadien"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107519_bb0485","first-page":"1269","article-title":"Canadian guideline for safe and effective use of opioids for chronic noncancer pain: Clinical summary for family physicians. Part 2: Special populations","volume":"57","author":"Kahan","year":"2011","journal-title":"Canadian family physician Medecin de famille canadien"},{"issue":"20","key":"10.1016\/j.pharmthera.2020.107519_bb0490","first-page":"2211","article-title":"New opioid preparations in the treatment of pain","volume":"115","author":"Kalso","year":"1999","journal-title":"Duodecim; Laaketieteellinen Aikakauskirja"},{"issue":"7484","key":"10.1016\/j.pharmthera.2020.107519_bb0495","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/bmj.330.7484.156","article-title":"Opioids for persistent non-cancer pain","volume":"330","author":"Kalso","year":"2005","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107519_bb0500","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1090-3801(02)00143-X","article-title":"Recommendations for using opioids in chronic non-cancer pain","volume":"7","author":"Kalso","year":"2003","journal-title":"European Journal of Pain (London, England)"},{"key":"10.1016\/j.pharmthera.2020.107519_bb0505","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-3-662-46450-2_2","article-title":"The pharmacology of nociceptor priming","volume":"227","author":"Kandasamy","year":"2015","journal-title":"Handbook of Experimental Pharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107519_bb0510","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/0006-8993(89)90974-8","article-title":"Potent antinociceptive effects of kelatorphan (a highly efficient inhibitor of multiple enkephalin-degrading enzymes) systemically administered in normal and arthritic rats","volume":"497","author":"Kayser","year":"1989","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2020.107519_bb0515","doi-asserted-by":"crossref","DOI":"10.1097\/j.pain.0000000000001524","article-title":"Targeting the CaV\u03b1-CaV\u03b2 interaction yields an antagonist of the N-type CaV2.2 channel with broad antinociceptive efficacy","author":"Khanna","year":"2019","journal-title":"Pain"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107519_bb0520","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1523\/JNEUROSCI.4298-03.2004","article-title":"Differential effects of CB1 and opioid agonists on two populations of adult rat dorsal root ganglion neurons","volume":"24","author":"Khasabova","year":"2004","journal-title":"The Journal of Neuroscience: The Official Journal of the Society for Neuroscience"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107519_bb0525","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1152\/jn.1997.77.3.1418","article-title":"Modulation of high-voltage activated Ca2+ channels in the rat periaqueductal gray neurons by mu-type opioid agonist","volume":"77","author":"Kim","year":"1997","journal-title":"Journal of Neurophysiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107519_bb0530","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41467-018-08162-1","article-title":"Phosphorylation-deficient G-protein-biased \u03bc-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects","volume":"10","author":"Kliewer","year":"2019","journal-title":"Nature Communications"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107519_bb0535","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1476-5381.1980.tb10422.x","article-title":"Effects of changes in the structure of enkephalins and of narcotic analgesic drugs on their interactions with mu- and delta-receptors","volume":"68","author":"Kosterlitz","year":"1980","journal-title":"British Journal of Pharmacology"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107519_bb0540","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1097\/j.pain.0000000000000846","article-title":"Primidone inhibits TRPM3 and attenuates thermal nociception in vivo","volume":"158","author":"Kr\u00fcgel","year":"2017","journal-title":"Pain"},{"issue":"16","key":"10.1016\/j.pharmthera.2020.107519_bb0545","first-page":"1632","article-title":"Chronic Pain Prevalence","volume":"320","author":"Kuehn","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2020.107519_bb0550","doi-asserted-by":"crossref","DOI":"10.1177\/1756284819841290","article-title":"Impact of patient and disease characteristics on the efficacy and safety of eluxadoline for IBS-D: A subgroup analysis of phase III trials","volume":"12","author":"Lacy","year":"2019","journal-title":"Therapeutic Advances in Gastroenterology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107519_bb0555","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.neulet.2008.03.088","article-title":"Pronociceptive actions of dynorphin via bradykinin receptors","volume":"437","author":"Lai","year":"2008","journal-title":"Neuroscience Letters"},{"key":"10.1016\/j.pharmthera.2020.107519_bb0560","first-page":"1","article-title":"Assessment of potentially abuse-related events in two phase 3 studies of NKTR-181, a novel opioid analgesic, using the MADDERS\u00ae system (misuse, abuse, and diversion drug event reporting system)","author":"Lanier","year":"2019","journal-title":"Current Medical Research and Opinion"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107519_bb0565","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/BF02197187","article-title":"Opioids for chronic pain of non-malignant origin--caring or crippling","volume":"3","author":"Large","year":"1995","journal-title":"Health Care Analysis: HCA: Journal of Health Philosophy and Policy"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107519_bb0570","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1124\/jpet.113.205245","article-title":"Building a better analgesic: Multifunctional compounds that address injury-induced pathology to enhance analgesic efficacy while eliminating unwanted side effects","volume":"347","author":"Largent-Milnes","year":"2013","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2020.107519_bb0575","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0304-3959(02)00486-4","article-title":"Pain management by a new series of dual inhibitors of enkephalin degrading enzymes: Long lasting antinociceptive properties and potentiation by CCK2 antagonist or methadone","volume":"104","author":"Le Guen","year":"2003","journal-title":"Pain"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107519_bb0580","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1124\/jpet.107.132233","article-title":"Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats","volume":"326","author":"Lehto","year":"2008","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107519_bb0585","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa1505180","article-title":"Eluxadoline for irritable bowel syndrome with diarrhea","volume":"374","author":"Lembo","year":"2016","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107519_bb0590","doi-asserted-by":"crossref","first-page":"F793","DOI":"10.1152\/ajprenal.2000.279.5.F793","article-title":"Molecular and functional properties of two-pore-domain potassium channels. American Journal of Physiology","volume":"279","author":"Lesage","year":"2000","journal-title":"Renal Physiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107519_bb0595","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0028-3908(02)00339-8","article-title":"Pharmacology of neuronal background potassium channels","volume":"44","author":"Lesage","year":"2003","journal-title":"Neuropharmacology"},{"issue":"5656","key":"10.1016\/j.pharmthera.2020.107519_bb0600","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/272826a0","article-title":"The narcotic antagonist naloxone enhances clinical pain","volume":"272","author":"Levine","year":"1978","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.pharmthera.2020.107519_bb0605","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1113\/JP270822","article-title":"\u03bc opioid receptor activation hyperpolarizes respiratory-controlling K\u00f6lliker-fuse neurons and suppresses post-inspiratory drive","volume":"593","author":"Levitt","year":"2015","journal-title":"The Journal of Physiology"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107519_bb0610","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s00540-014-1795-9","article-title":"Evaluation of the peripheral analgesic effect of sufentanil lipid nanoparticles","volume":"28","author":"Li","year":"2014","journal-title":"Journal of Anesthesia"},{"key":"10.1016\/j.pharmthera.2020.107519_bb0615","article-title":"Pharmacological characters of Oliceridine, a \u03bc-opioid receptor G-protein[FIGURE DASH]biased ligand in mice","author":"Liang","year":"2018","journal-title":"Anesthesia and Analgesia"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107519_bb0620","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/ALN.0000000000002031","article-title":"Abuse-deterrent opioid formulations","volume":"128","author":"Litman","year":"2018","journal-title":"Anesthesiology: The Journal of the American Society of Anesthesiologists"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107519_bb0625","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0163-7258(91)90050-V","article-title":"The role of neuronal calcium channels in dependence on ethanol and other sedatives\/hypnotics","volume":"50","author":"Little","year":"1991","journal-title":"Pharmacology & Therapeutics"},{"issue":"4962","key":"10.1016\/j.pharmthera.2020.107519_bb0630","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1126\/science.2163110","article-title":"Beta-Arrestin: A protein that regulates beta-adrenergic receptor function","volume":"248","author":"Lohse","year":"1990","journal-title":"Science (New York, N.Y.)"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107519_bb0635","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1172\/JCI81070","article-title":"Mediation of opioid analgesia by a truncated 6-transmembrane GPCR","volume":"125","author":"Lu","year":"2015","journal-title":"Journal of Clinical Investigation"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107519_bb0640","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrn2834","article-title":"Emerging roles for G protein-gated inwardly rectifying potassium (GIRK) channels in health and disease","volume":"11","author":"L\u00fcscher","year":"2010","journal-title":"Nature Reviews Neuroscience"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107519_bb0645","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1097\/j.pain.0000000000000676","article-title":"The epidemiology of chronic pain","volume":"157","author":"Macfarlane","year":"2016","journal-title":"Pain"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107519_bb0650","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1093\/emboj\/19.11.2483","article-title":"TREK-1 is a heat-activated background K(+) channel","volume":"19","author":"Maingret","year":"2000","journal-title":"The EMBO Journal"},{"issue":"49","key":"10.1016\/j.pharmthera.2020.107519_bb0655","doi-asserted-by":"crossref","first-page":"19778","DOI":"10.1073\/pnas.1115231108","article-title":"Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects","volume":"108","author":"Majumdar","year":"2011","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"3 Suppl","key":"10.1016\/j.pharmthera.2020.107519_bb0660","first-page":"S67","article-title":"American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2--guidance","volume":"15","author":"Manchikanti","year":"2012","journal-title":"Pain Physician"},{"issue":"3 Suppl","key":"10.1016\/j.pharmthera.2020.107519_bb0665","first-page":"S1","article-title":"American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part I--evidence assessment","volume":"15","author":"Manchikanti","year":"2012","journal-title":"Pain Physician"},{"issue":"3 Suppl","key":"10.1016\/j.pharmthera.2020.107519_bb0670","doi-asserted-by":"crossref","first-page":"ES9","DOI":"10.36076\/ppj.2012\/15\/ES9","article-title":"Opioid epidemic in the United States","volume":"15","author":"Manchikanti","year":"2012","journal-title":"Pain Physician"},{"issue":"2S","key":"10.1016\/j.pharmthera.2020.107519_bb0675","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.36076\/ppj.2017.s92","article-title":"Responsible, safe, and effective prescription of opioids for chronic non-cancer pain: American Society of Interventional Pain Physicians (ASIPP) guidelines","volume":"20","author":"Manchikanti","year":"2017","journal-title":"Pain Physician"},{"issue":"7619","key":"10.1016\/j.pharmthera.2020.107519_bb0680","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature19112","article-title":"Structure-based discovery of opioid analgesics with reduced side effects","volume":"537","author":"Manglik","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107519_bb0685","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.neuropharm.2017.06.019","article-title":"Two delta opioid receptor subtypes are functional in single ventral tegmental area neurons, and can interact with the mu opioid receptor","volume":"123","author":"Margolis","year":"2017","journal-title":"Neuropharmacology"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107519_bb0690","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1523\/JNEUROSCI.5251-03.2004","article-title":"Spinal G-protein-gated K+ channels formed by GIRK1 and GIRK2 subunits modulate thermal nociception and contribute to morphine analgesia","volume":"24","author":"Marker","year":"2004","journal-title":"The Journal of Neuroscience: The Official Journal of the Society for Neuroscience"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107519_bb0695","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1097\/j.pain.0000000000001517","article-title":"SUMMIT-07: A randomized trial of NKTR-181, a new molecular entity, full mu-opioid receptor agonist for chronic low-back pain","volume":"160","author":"Markman","year":"2019","journal-title":"Pain"},{"issue":"47","key":"10.1016\/j.pharmthera.2020.107519_bb0700","doi-asserted-by":"crossref","first-page":"12183","DOI":"10.1523\/JNEUROSCI.2326-08.2008","article-title":"A novel Gbetagamma-subunit inhibitor selectively modulates mu-opioid-dependent antinociception and attenuates acute morphine-induced antinociceptive tolerance and dependence","volume":"28","author":"Mathews","year":"2008","journal-title":"The Journal of Neuroscience: The Official Journal of the Society for Neuroscience"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107519_bb0705","first-page":"555","article-title":"Therapeutic potential of neuronal two-pore domain potassium-channel modulators","volume":"8","author":"Mathie","year":"2007","journal-title":"Current Opinion in Investigational Drugs (London, England: 2000)"},{"issue":"6603","key":"10.1016\/j.pharmthera.2020.107519_bb0710","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/383819a0","article-title":"Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene","volume":"383","author":"Matthes","year":"1996","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107519_bb0715","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/scientificamerican0290-27","article-title":"The tragedy of needless pain","volume":"262","author":"Melzack","year":"1990","journal-title":"Scientific American"},{"issue":"1\u20133","key":"10.1016\/j.pharmthera.2020.107519_bb0720","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejphar.2008.07.043","article-title":"Inhibition of osteosarcoma-induced thermal hyperalgesia in mice by the orally active dual enkephalinase inhibitor PL37. Potentiation by gabapentin","volume":"596","author":"Men\u00e9ndez","year":"2008","journal-title":"European Journal of Pharmacology"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107519_bb0725","first-page":"201","article-title":"Potent analgesic effects of inhibitors of enkephalin metabolism administered intrathecally to cancer patients","volume":"2","author":"Meynadier","year":"1988","journal-title":"The Pain Clinic"},{"key":"10.1016\/j.pharmthera.2020.107519_bb0730","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.actpsy.2013.10.009","article-title":"Classical conditioning and pain: Conditioned analgesia and hyperalgesia","volume":"145","author":"Miguez","year":"2014","journal-title":"Acta Psychologica"},{"issue":"8967","key":"10.1016\/j.pharmthera.2020.107519_bb0735","article-title":"Endogenous opioids contribute to insensitivity to pain in humans and mice lacking sodium channel Nav1.7","volume":"6","author":"Minett","year":"2015","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2020.107519_bb0740","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3389\/fnbeh.2012.00060","article-title":"Behavioral characterization of mice lacking Trek channels","volume":"6","author":"Mirkovic","year":"2012","journal-title":"Frontiers in Behavioral Neuroscience"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107519_bb0745","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1073\/pnas.0136822100","article-title":"Contribution of GIRK2-mediated postsynaptic signaling to opiate and alpha 2-adrenergic analgesia and analgesic sex differences","volume":"100","author":"Mitrovic","year":"2003","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107519_bb0750","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1124\/jpet.117.243030","article-title":"NKTR-181: A novel mu-opioid analgesic with inherently low abuse potential","volume":"363","author":"Miyazaki","year":"2017","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2020.107519_bb0755","doi-asserted-by":"crossref","first-page":"32707","DOI":"10.1038\/srep32707","article-title":"Contribution of the respiratory network to rhythm and motor output revealed by modulation of GIRK channels, somatostatin and neurokinin-1 receptors","volume":"6","author":"Montandon","year":"2016","journal-title":"Scientific Reports"},{"issue":"40","key":"10.1016\/j.pharmthera.2020.107519_bb0760","doi-asserted-by":"crossref","first-page":"13419","DOI":"10.1523\/JNEUROSCI.2966-10.2010","article-title":"Morphine- and CaMKII-dependent enhancement of GIRK channel signaling in hippocampal neurons","volume":"30","author":"Nassirpour","year":"2010","journal-title":"The Journal of Neuroscience: The Official Journal of the Society for Neuroscience"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107519_bb0765","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/bja\/aeq212","article-title":"Effects of capsazepine, a transient receptor potential vanilloid type 1 antagonist, on morphine-induced antinociception, tolerance, and dependence in mice","volume":"105","author":"Nguyen","year":"2010","journal-title":"British Journal of Anaesthesia"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107519_bb0770","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.neuroscience.2007.05.049","article-title":"Bone cancer increases transient receptor potential vanilloid subfamily 1 expression within distinct subpopulations of dorsal root ganglion neurons","volume":"148","author":"Niiyama","year":"2007","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107519_bb0775","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00213-007-0964-z","article-title":"Use of preproenkephalin knockout mice and selective inhibitors of enkephalinases to investigate the role of enkephalins in various behaviours","volume":"196","author":"Noble","year":"2008","journal-title":"Psychopharmacology"},{"issue":"5846","key":"10.1016\/j.pharmthera.2020.107519_bb0780","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/295202a0","article-title":"Cloning and sequence analysis of cDNA for bovine adrenal preproenkephalin","volume":"295","author":"Noda","year":"1982","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107519_bb0785","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/emboj.2009.57","article-title":"The mechano-activated K+ channels TRAAK and TREK-1 control both warm and cold perception","volume":"28","author":"No\u00ebl","year":"2009","journal-title":"The EMBO Journal"},{"issue":"6027","key":"10.1016\/j.pharmthera.2020.107519_bb0790","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/316440a0","article-title":"Three types of neuronal calcium channel with different calcium agonist sensitivity","volume":"316","author":"Nowycky","year":"1985","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107519_bb0795","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1124\/pr.112.006163","article-title":"Unravelling the mystery of capsaicin: A tool to understand and treat pain","volume":"64","author":"O\u2019Neill","year":"2012","journal-title":"Pharmacological Reviews"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107519_bb0800","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1073\/pnas.0811586106","article-title":"Involvement of exon 11-associated variants of the mu opioid receptor MOR-1 in heroin, but not morphine, actions","volume":"106","author":"Pan","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107519_bb0805","series-title":"Proceedings of the National Academy of Sciences of the United States of America","first-page":"14857","article-title":"T-type channels control the opioidergic descending analgesia at the low threshold-spiking GABAergic neurons in the periaqueductal gray","volume":"33","author":"Park","year":"2010"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107519_bb0810","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1124\/pr.112.007138","article-title":"Mu opioids and their receptors: Evolution of a concept","volume":"65","author":"Pasternak","year":"2013","journal-title":"Pharmacological Reviews"},{"issue":"15","key":"10.1016\/j.pharmthera.2020.107519_bb0815","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1093\/emboj\/17.15.4283","article-title":"A mammalian two pore domain mechano-gated S-like K+ channel","volume":"17","author":"Patel","year":"1998","journal-title":"The EMBO Journal"},{"key":"10.1016\/j.pharmthera.2020.107519_bb0820","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1186\/s13063-015-1021-6","article-title":"Effect of a high-dose target-controlled naloxone infusion on pain and hyperalgesia in patients following groin hernia repair: Study protocol for a randomized controlled trial","volume":"16","author":"Pereira","year":"2015","journal-title":"Trials"},{"issue":"101","key":"10.1016\/j.pharmthera.2020.107519_bb0825","article-title":"Analgesia linked to Nav1.7 loss of function requires \u03bc- and \u03b4-opioid receptors","volume":"3","author":"Pereira","year":"2018","journal-title":"Wellcome Open Research"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107519_bb0830","first-page":"606","article-title":"Long-term administration of opioids for non-tumor pain - LONTS guideline provides an orientation","volume":"50","author":"Petzke","year":"2015","journal-title":"Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie: AINS"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107519_bb0835","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0304-3959(97)00040-7","article-title":"Analgesic efficacy of peripheral opioids (all except intra-articular): A qualitative systematic review of randomised controlled trials","volume":"72","author":"Picard","year":"1997","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2020.107519_bb0840","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1146\/annurev-pharmtox-010715-103042","article-title":"The emerging role of spinal Dynorphin in chronic pain: A therapeutic perspective","volume":"56","author":"Podvin","year":"2016","journal-title":"Annual Review of Pharmacology and Toxicology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107519_bb0845","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.bbr.2010.04.045","article-title":"Human opiorphin: The lack of physiological dependence, tolerance to antinociceptive effects and abuse liability in laboratory mice","volume":"213","author":"Popik","year":"2010","journal-title":"Behavioural Brain Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107519_bb0850","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0304-3959(86)90091-6","article-title":"Chronic use of opioid analgesics in non-malignant pain: Report of 38 cases","volume":"25","author":"Portenoy","year":"1986","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2020.107519_bb0855","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.neuropharm.2018.07.026","article-title":"Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin","volume":"140","author":"Poupon","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2020.107519_bb0860","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.26138","article-title":"G protein \u03b2\u03b3 subunits inhibit TRPM3 ion channels in sensory neurons","volume":"6","author":"Quallo","year":"2017","journal-title":"ELife"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107519_bb0865","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1124\/jpet.105.087254","article-title":"Morphine side effects in beta-arrestin 2 knockout mice","volume":"314","author":"Raehal","year":"2005","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107519_bb0870","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/jcpt.12687","article-title":"Indirect-acting strategy of opioid action instead of direct receptor activation: Dual-acting enkephalinase inhibitors (DENKIs)","volume":"43","author":"Raffa","year":"2018","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107519_bb0875","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1124\/jpet.111.190314","article-title":"Pharmacology of modality-specific transient receptor potential vanilloid-1 antagonists that do not alter body temperature","volume":"342","author":"Reilly","year":"2012","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107519_bb0880","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s00482-009-0839-9","article-title":"S3 guideline LONTS. Long-term administration of opioids for non-tumor pain","volume":"23","author":"Reinecke","year":"2009","journal-title":"Schmerz (Berlin, Germany)"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107519_bb0885","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/bph.12634","article-title":"Analgesic efficacy of opioids in chronic pain: Recent meta-analyses","volume":"172","author":"Reinecke","year":"2015","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107519_bb0890","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ejmech.2014.01.049","article-title":"Synthesis and structure-activity relationship study of substituted caffeate esters as antinociceptive agents modulating the TREK-1 channel","volume":"75","author":"Rodrigues","year":"2014","journal-title":"European Journal of Medicinal Chemistry"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107519_bb0895","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1097\/j.pain.0000000000001328","article-title":"Analgesic effects of a novel pH-dependent \u03bc-opioid receptor agonist in models of neuropathic and abdominal pain","volume":"159","author":"Rodriguez-Gaztelumendi","year":"2018","journal-title":"Pain"},{"issue":"5788","key":"10.1016\/j.pharmthera.2020.107519_bb0900","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/288286a0","article-title":"The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice","volume":"288","author":"Roques","year":"1980","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107519_bb0905","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/nrd3673","article-title":"Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain. Nature Reviews","volume":"11","author":"Roques","year":"2012","journal-title":"Drug Discovery"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107519_bb0910","first-page":"483","article-title":"Systemically active human opiorphin is a potent yet non-addictive analgesic without drug tolerance effects","volume":"61","author":"Rougeot","year":"2010","journal-title":"Journal of Physiology and Pharmacology: An Official Journal of the Polish Physiological Society"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107519_bb0915","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0093688","article-title":"Activation of mu opioid receptors sensitizes transient receptor potential vanilloid type 1 (TRPV1) via \u03b2-arrestin-2-mediated cross-talk","volume":"9","author":"Rowan","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107519_bb0920","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.mayocp.2017.12.020","article-title":"How good intentions contributed to bad outcomes: The opioid crisis","volume":"93","author":"Rummans","year":"2018","journal-title":"Mayo Clinic Proceedings"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107519_bb0925","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1073\/pnas.100124197","article-title":"Altered pain responses in mice lacking alpha 1E subunit of the voltage-dependent Ca2+ channel","volume":"97","author":"Saegusa","year":"2000","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107519_bb0930","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s40263-013-0107-5","article-title":"Intrathecal ziconotide: A review of its use in patients with chronic pain refractory to other systemic or intrathecal analgesics","volume":"27","author":"Sanford","year":"2013","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107519_bb0935","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.cell.2017.10.035","article-title":"Bias factor and therapeutic window correlate to predict safer opioid analgesics","volume":"171","author":"Schmid","year":"2017","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107519_bb0940","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/5706","article-title":"Retention of heroin and morphine-6 beta-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1","volume":"2","author":"Schuller","year":"1999","journal-title":"Nature Neuroscience"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107519_bb0945","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/syn.20612","article-title":"Direct evidence for the up-regulation of Vps34 regulated by PKCgamma during short-term treatment with morphine","volume":"63","author":"Shibasaki","year":"2009","journal-title":"Synapse (New York, N.Y.)"},{"issue":"1\u20133","key":"10.1016\/j.pharmthera.2020.107519_bb0950","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejphar.2010.11.013","article-title":"Up-regulation of Ca(v)1.2 subunit via facilitating trafficking induced by Vps34 on morphine-induced place preference in mice","volume":"651","author":"Shibasaki","year":"2011","journal-title":"European Journal of Pharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107519_bb0955","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s40122-018-0096-7","article-title":"A review of the opioid epidemic: What do we do about it?","volume":"7","author":"Shipton","year":"2018","journal-title":"Pain and therapy"},{"key":"10.1016\/j.pharmthera.2020.107519_bb0960","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.2147\/JPR.S137952","article-title":"A randomized, phase IIb study investigating oliceridine (TRV130), a novel \u03bc-receptor G-protein pathway selective (\u03bc-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty","volume":"10","author":"Singla","year":"2017","journal-title":"Journal of Pain Research"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107519_bb0965","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/papr.12801","article-title":"APOLLO-2: A randomized, placebo and active-controlled phase III study investigating Oliceridine (TRV130), a G protein-biased ligand at the \u03bc-opioid receptor, for Management of Moderate to severe acute pain following abdominoplasty","volume":"19","author":"Singla","year":"2019","journal-title":"Pain Practice: The Official Journal of World Institute of Pain"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107519_bb0970","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1097\/ALN.0000000000001320","article-title":"STR-324, a stable analog of Opiorphin, causes analgesia in postoperative pain by activating endogenous opioid receptor-dependent pathways","volume":"125","author":"Sitbon","year":"2016","journal-title":"Anesthesiology"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107519_bb0975","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.pain.2014.06.011","article-title":"Biased agonism of the \u03bc-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers","volume":"155","author":"Soergel","year":"2014","journal-title":"Pain"},{"issue":"6328","key":"10.1016\/j.pharmthera.2020.107519_bb0980","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1126\/science.aai8636","article-title":"A nontoxic pain killer designed by modeling of pathological receptor conformations","volume":"355","author":"Spahn","year":"2017","journal-title":"Science (New York, N.Y.)"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107519_bb0985","doi-asserted-by":"crossref","first-page":"8965","DOI":"10.1038\/s41598-018-27313-4","article-title":"Opioid receptor signaling, analgesic and side effects induced by a computationally designed pH-dependent agonist","volume":"8","author":"Spahn","year":"2018","journal-title":"Scientific Reports"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107519_bb0990","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.pain.2012.12.026","article-title":"Opioid withdrawal increases transient receptor potential vanilloid 1 activity in a protein kinase A-dependent manner","volume":"154","author":"Spahn","year":"2013","journal-title":"Pain"},{"issue":"16","key":"10.1016\/j.pharmthera.2020.107519_bb0995","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJM199110173251602","article-title":"Analgesic effect of intraarticular morphine after arthroscopic knee surgery","volume":"325","author":"Stein","year":"1991","journal-title":"The New England Journal of Medicine"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107519_bb1000","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/13543784.2018.1516204","article-title":"New concepts in opioid analgesia","volume":"27","author":"Stein","year":"2018","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107519_bb1005","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1124\/pr.110.003145","article-title":"Modulation of peripheral sensory neurons by the immune system: Implications for pain therapy","volume":"63","author":"Stein","year":"2011","journal-title":"Pharmacological Reviews"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107519_bb1010","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.neuron.2018.04.021","article-title":"A genetically encoded biosensor reveals location bias of opioid drug action","volume":"98","author":"Stoeber","year":"2018","journal-title":"Neuron"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107519_bb1015","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1124\/mol.113.086843","article-title":"Flavanones that selectively inhibit TRPM3 attenuate thermal nociception in vivo","volume":"84","author":"Straub","year":"2013","journal-title":"Molecular Pharmacology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107519_bb1020","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1152\/jn.00624.2001","article-title":"Sodium channel blocking actions of the kappa-opioid receptor agonist U50,488 contribute to its visceral antinociceptive effects","volume":"87","author":"Su","year":"2002","journal-title":"Journal of Neurophysiology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107519_bb1025","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.232","article-title":"Diclofenac, a nonsteroidal anti-inflammatory drug, is an antagonist of human TRPM3 isoforms","volume":"4","author":"Suzuki","year":"2016","journal-title":"Pharmacology Research & Perspectives"},{"key":"10.1016\/j.pharmthera.2020.107519_bb1030","series-title":"Handbook of hormones: Comparative endocrinology for basic and clinical research","author":"Takei","year":"2015"},{"issue":"51","key":"10.1016\/j.pharmthera.2020.107519_bb1035","doi-asserted-by":"crossref","first-page":"35614","DOI":"10.1074\/jbc.M806588200","article-title":"Alternative splicing determines the post-endocytic sorting fate of G-protein-coupled receptors","volume":"283","author":"Tanowitz","year":"2008","journal-title":"The Journal of Biological Chemistry"},{"issue":"Pt 5","key":"10.1016\/j.pharmthera.2020.107519_bb1040","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/brain\/awg115","article-title":"Peripheral opioid analgesia in experimental human pain models","volume":"126","author":"Tegeder","year":"2003","journal-title":"Brain: A Journal of Neurology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107519_bb1045","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/00002508-199703000-00003","volume":"13","author":"The use of opioids for the treatment of chronic pain. A consensus statement from the American Academy of Pain Medicine and the American Pain Society","year":"1997","journal-title":"The Clinical Journal of Pain"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107519_bb1050","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.peptides.2009.04.002","article-title":"Effects and underlying mechanisms of human opiorphin on colonic motility and nociception in mice","volume":"30","author":"Tian","year":"2009","journal-title":"Peptides"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107519_bb1055","first-page":"1","article-title":"Opioid guidelines in the management of chronic non-cancer pain","volume":"9","author":"Trescot","year":"2006","journal-title":"Pain Physician"},{"issue":"2 Suppl","key":"10.1016\/j.pharmthera.2020.107519_bb1060","first-page":"S5","article-title":"Opioids in the management of chronic non-cancer pain: An update of American Society of the Interventional Pain Physicians\u2019 (ASIPP) guidelines","volume":"11","author":"Trescot","year":"2008","journal-title":"Pain Physician"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107519_bb1065","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0304-3959(94)90072-8","article-title":"Physicians\u2019 attitudes and practices regarding the long-term prescribing of opioids for non-cancer pain","volume":"59","author":"Turk","year":"1994","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2020.107519_bb1070","series-title":"World drug report 2018 - analysis of drug markets","first-page":"76","author":"UNDOC","year":"2018"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107519_bb1075","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/187447370801150611184218","article-title":"The misuse of prescription opioids: A threat for Europe?","volume":"8","author":"Van Amsterdam","year":"2015","journal-title":"Current Drug Abuse Reviews"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107519_bb1080","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1213\/ANE.0000000000002413","article-title":"The Opiorphin analog STR-324 decreases sensory hypersensitivity in a rat model of neuropathic pain","volume":"126","author":"Van Elstraete","year":"2018","journal-title":"Anesthesia and Analgesia"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107519_bb1085","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jpain.2008.07.004","article-title":"TRPV1 receptor in expression of opioid-induced hyperalgesia","volume":"10","author":"Vardanyan","year":"2009","journal-title":"The Journal of Pain: Official Journal of the American Pain Society"},{"issue":"14","key":"10.1016\/j.pharmthera.2020.107519_bb1090","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.2174\/156802612802652457","article-title":"Therapeutic potential of cone snail venom peptides (conopeptides)","volume":"12","author":"Vetter","year":"2012","journal-title":"Current Topics in Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107519_bb1095","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1744-8069-2-22","article-title":"The mu opioid agonist morphine modulates potentiation of capsaicin-evoked TRPV1 responses through a cyclic AMP-dependent protein kinase A pathway","volume":"2","author":"Vetter","year":"2006","journal-title":"Molecular Pain"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107519_bb1100","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.tips.2007.06.006","article-title":"Beta-arrestin-biased ligands at seven-transmembrane receptors","volume":"28","author":"Violin","year":"2007","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2020.107519_bb1105","doi-asserted-by":"crossref","first-page":"927","DOI":"10.2147\/JPR.S171013","article-title":"APOLLO-1: A randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the \u03bc-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy","volume":"12","author":"Viscusi","year":"2019","journal-title":"Journal of Pain Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107519_bb1110","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/j.pain.0000000000000363","article-title":"A randomized, phase 2 study investigating TRV130, a biased ligand of the \u03bc-opioid receptor, for the intravenous treatment of acute pain","volume":"157","author":"Viscusi","year":"2016","journal-title":"Pain"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107519_bb1115","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1021\/acs.jmedchem.5b00671","article-title":"Perspectives on the two-pore domain Potassium Channel TREK-1 (TWIK-related K(+) channel 1). A novel therapeutic target?","volume":"59","author":"Vivier","year":"2016","journal-title":"Journal of Medicinal Chemistry"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107519_bb1120","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1021\/acs.jmedchem.6b01285","article-title":"Development of the first two-pore domain Potassium Channel TWIK-related K+ channel 1-selective agonist possessing in vivo Antinociceptive activity","volume":"60","author":"Vivier","year":"2017","journal-title":"Journal of Medicinal Chemistry"},{"issue":"17","key":"10.1016\/j.pharmthera.2020.107519_bb1125","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1021\/jm500916t","article-title":"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): A temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy","volume":"57","author":"Voight","year":"2014","journal-title":"Journal of Medicinal Chemistry"},{"issue":"13","key":"10.1016\/j.pharmthera.2020.107519_bb1130","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJMra1507771","article-title":"Opioid abuse in chronic pain \u2014 Misconceptions and mitigation strategies","volume":"374","author":"Volkow","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107519_bb1135","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.neuron.2011.02.051","article-title":"TRPM3 is a nociceptor channel involved in the detection of noxious heat","volume":"70","author":"Vriens","year":"2011","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107519_bb1140","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0197-0186(99)00050-9","article-title":"Regulation of neuronal voltage-gated calcium channels by ethanol","volume":"35","author":"Walter","year":"1999","journal-title":"Neurochemistry International"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107519_bb1145","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/pm\/pnw344","article-title":"Human abuse potential of the new opioid analgesic molecule NKTR-181 compared with oxycodone","volume":"19","author":"Webster","year":"2018","journal-title":"Pain Medicine (Malden, Mass.)"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107519_bb1150","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/AJP.0000000000000012","article-title":"Single-dose intra-articular bupivacaine versus morphine after arthroscopic knee surgery: A meta-analysis of randomized-controlled studies","volume":"30","author":"Wei","year":"2014","journal-title":"The Clinical Journal of Pain"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107519_bb1155","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/j.pain.2014.07.014","article-title":"Broad-spectrum analgesic efficacy of IBNtxA is mediated by exon 11-associated splice variants of the mu-opioid receptor gene","volume":"155","author":"Wieskopf","year":"2014","journal-title":"Pain"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107519_bb1160","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1152\/physrev.2001.81.1.299","article-title":"Cellular and synaptic adaptations mediating opioid dependence","volume":"81","author":"Williams","year":"2001","journal-title":"Physiological Reviews"},{"issue":"47","key":"10.1016\/j.pharmthera.2020.107519_bb1165","doi-asserted-by":"crossref","first-page":"17979","DOI":"10.1073\/pnas.0605865103","article-title":"Human Opiorphin, a natural antinociceptive modulator of opioid-dependent pathways","volume":"103","author":"Wisner","year":"2006","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107519_bb1170","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.brainres.2006.03.119","article-title":"Opioid mu receptor activation inhibits sodium currents in prefrontal cortical neurons via a protein kinase A- and C-dependent mechanism","volume":"1094","author":"Witkowski","year":"2006","journal-title":"Brain Research"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107519_bb1175","first-page":"768","article-title":"Blood-brain barrier permeability to morphine-6-glucuronide is markedly reduced compared with morphine","volume":"25","author":"Wu","year":"1997","journal-title":"Drug Metabolism and Disposition: The Biological Fate of Chemicals"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107519_bb1180","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1124\/jpet.104.073429","article-title":"Differential sensitivity of N- and P\/Q-type Ca2+ channel currents to a mu opioid in isolectin B4-positive and -negative dorsal root ganglion neurons","volume":"311","author":"Wu","year":"2004","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107519_bb1185","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1073\/pnas.1419183112","article-title":"Stabilization of morphine tolerance with long-term dosing: Association with selective upregulation of mu-opioid receptor splice variant mRNAs","volume":"112","author":"Xu","year":"2015","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107519_bb1190","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1172\/JCI88760","article-title":"Alternatively spliced mu opioid receptor C termini impact the diverse actions of morphine","volume":"127","author":"Xu","year":"2017","journal-title":"The Journal of Clinical Investigation"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107519_bb1195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111267","article-title":"Differential expressions of the alternatively spliced variant mRNAs of the \u03bc opioid receptor gene, OPRM1, in brain regions of four inbred mouse strains","volume":"9","author":"Xu","year":"2014","journal-title":"PLoS One"},{"issue":"29","key":"10.1016\/j.pharmthera.2020.107519_bb1200","doi-asserted-by":"crossref","first-page":"21211","DOI":"10.1074\/jbc.M113.458687","article-title":"Stabilization of the \u03bc-opioid receptor by truncated single transmembrane splice variants through a chaperone-like action","volume":"288","author":"Xu","year":"2013","journal-title":"The Journal of Biological Chemistry"},{"issue":"19","key":"10.1016\/j.pharmthera.2020.107519_bb1205","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1523\/JNEUROSCI.5552-03.2004","article-title":"Neuropathic pain activates the endogenous kappa opioid system in mouse spinal cord and induces opioid receptor tolerance","volume":"24","author":"Xu","year":"2004","journal-title":"The Journal of Neuroscience: The Official Journal of the Society for Neuroscience"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107519_bb1210","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1073\/pnas.1016277108","article-title":"N-naphthoyl-beta-naltrexamine (NNTA), a highly selective and potent activator of \u03bc\/kappa-opioid heteromers","volume":"108","author":"Yekkirala","year":"2011","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107519_bb1215","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1111\/j.1460-9568.2004.03810.x","article-title":"Blocking the R-type (Cav2.3) Ca2+ channel enhanced morphine analgesia and reduced morphine tolerance","volume":"20","author":"Yokoyama","year":"2004","journal-title":"The European Journal of Neuroscience"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107519_bb1220","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.bbamem.2012.10.004","article-title":"Regulation of ca(V)2 calcium channels by G protein coupled receptors","volume":"1828","author":"Zamponi","year":"2013","journal-title":"Biochimica et Biophysica Acta"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107519_bb1225","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0006-8993(99)02360-4","article-title":"Blockade of U50488H on sodium currents in acutely isolated mice hippocampal CA3 pyramidal neurons","volume":"855","author":"Zou","year":"2000","journal-title":"Brain Research"},{"issue":"34","key":"10.1016\/j.pharmthera.2020.107519_bb1230","doi-asserted-by":"crossref","first-page":"7754","DOI":"10.1523\/JNEUROSCI.0439-05.2005","article-title":"Placebo effects mediated by endogenous opioid activity on mu-opioid receptors","volume":"25","author":"Zubieta","year":"2005","journal-title":"The Journal of Neuroscience: The Official Journal of the Society for Neuroscience"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725820300474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725820300474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:08:53Z","timestamp":1759010933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725820300474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":244,"alternative-id":["S0163725820300474"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107519","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Replacement of current opioid drugs focusing on MOR-related strategies","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107519","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107519"}}